Compare Ascendis Pharma A/S (ASND) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Hormel Foods Corp — how do they compare? Ascendis Pharma A/S trades at $256.21 (market cap $16.67B), while Hormel Foods Corp trades at $24.23 (market cap $13.37B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Hormel Foods Corp pays a 4.81% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HRL | |
|---|---|---|
Market Cap | $16.67B | $13.37B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $29.25 |
52-Week Low | $189.74 | $19.74 |
Enterprise Value | $17.04B | $15.37B |
Dividend Yield | — | 4.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Hormel Foods (HRL) trades at $24.705, down 1.26% on the day, with a bearish technical signal and neutral oscillators. The company reported Q2 2026 EPS of $0.40, beating expectations, but net income margin declined to 3.82% in 2025. Recent news includes the appointment of John Ghingo as CEO and the sale of its Brazilian CERATTI business, signaling strategic refocusing.
Outlook is mixed: strong dividend yield and consistent earnings beats support income investors, but margin pressures and bearish technicals pose near-term risks. Analyst consensus is 'Hold' with a $26.33 price target, suggesting limited upside. Macroeconomic headwinds in consumer staples may challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
